



(11)

EP 2 760 994 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:

C12N 5/071 (2010.01) **C12N 7/01** (2006.01)
C12N 5/02 (2006.01) **C12N 5/0789** (2010.01)
A61K 38/46 (2006.01) **C12N 15/86** (2006.01)
A61K 35/12 (2015.01)

(48) Corrigendum issued on:

26.07.2017 Bulletin 2017/30

(86) International application number:

PCT/US2012/057987

(45) Date of publication and mention
of the grant of the patent:

31.05.2017 Bulletin 2017/22

(87) International publication number:

WO 2013/049615 (04.04.2013 Gazette 2013/14)

(21) Application number: **12836507.9**

(22) Date of filing: **28.09.2012**

(54) **COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTION**

VERBINDUNGEN FÜR VERBESSERTE VIRALE TRANSDUKTION

COMPOSÉS AMÉLIORANT LA TRANSDUCTION VIRALE

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(74) Representative: **Goodfellow, Hugh Robin et al**

Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA (GB)

(30) Priority: **30.09.2011 US 201161541736 P**

(56) References cited:

WO-A1-2010/054271 WO-A2-2004/098531
US-A1- 2009 092 589

(43) Date of publication of application:
06.08.2014 Bulletin 2014/32

(60) Divisional application:
17173567.3

(73) Proprietor: **Bluebird Bio, Inc.**
Cambridge, MA 02142 (US)

(72) Inventors:

- **HEFFNER, Garrett Collins**
Boston
Massachusetts 02215 (US)
- **BASSAN, Abraham Isaac**
Brookline
Massachusetts 02446 (US)

- **MOSTOSLAVSKY ET AL: "Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 11, no. 6, 1 June 2005 (2005-06-01), pages 932-940, XP005002713, ISSN: 1525-0016, DOI: 10.1016/J.YMTHE.2005.01.005**
- **GOESSLING W. ET AL.: 'Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models' CELL STEM CELL vol. 8, 08 April 2011, pages 445 - 458, XP055002056**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 760 994 B8

- | | |
|--|---|
| <ul style="list-style-type: none"> • PELUS L.M. ET AL.: 'Pleiotropic effects of prostaglandin E2 in hematopoiesis; prostaglandin E2 and other eicosanoids regulate hematopoietic stem and progenitor cell function' PROSTAGLANDINS & OTHER LIPID MEDIATORS vol. 96, 2011, pages 3 - 9, XP028108764 • N. Cartier ET AL: "Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy", Science, vol. 326, no. 5954, 6 November 2009 (2009-11-06), pages 818-823, XP055268270, US ISSN: 0036-8075, DOI: 10.1126/science.1171242 • G. Puthenveetil ET AL: "Successful correction of the human α-thalassemia major phenotype using a lentiviral vector", Blood, vol. 104, no. 12, 1 December 2004 (2004-12-01), pages 3445-3453, XP055216529, ISSN: 0006-4971, DOI: 10.1182/blood-2004-04-1427 | <ul style="list-style-type: none"> • PAWLIUK R ET AL: "Correction of sickle cell disease in transgenic mouse models of gene therapy", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 294, 14 December 2001 (2001-12-14), pages 2368-2371, XP002984304, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1065806 |
|--|---|